Rowe JM - Search Results

1

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Fernandez HF, et al. Among authors: rowe jm. Haematologica. 2019 Apr;104(4):e147-e150. doi: 10.3324/haematol.2018.197277. Epub 2018 Nov 22. Haematologica. 2019. PMID: 30467203 Free PMC article. Clinical Trial. No abstract available.

2

Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.

Dutcher JP, Eudey L, Wiernik PH, Paietta E, Bennett JM, Arlin Z, Kellermeyer R, Rowe J, O'Connell M, Oken M, et al. Dutcher JP, et al. Among authors: rowe j. Leukemia. 1992 Aug;6(8):770-5. Leukemia. 1992. PMID: 1379312 Clinical Trial.

3

Post-remission therapy in adults with acute myelogenous leukemia: the Eastern Cooperative Oncology Group (ECOG) experience.

Rowe JM, Andersen JW, Cassileth PA, Oken MM, Bennett JM, Wiernik PH. Rowe JM, et al. Leukemia. 1992 Nov;6 Suppl 4:75-7. Leukemia. 1992. PMID: 1434840 Clinical Trial. No abstract available.

4

Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia.

Rowe JM, Mazza JJ, Hines JD, Cassileth PA, Oken MM, Bennett JM, Andersen J. Rowe JM, et al. Haematol Blood Transfus. 1990;33:326-9. doi: 10.1007/978-3-642-74643-7_61. Haematol Blood Transfus. 1990. PMID: 2182427 Clinical Trial. No abstract available.

5

Treatment of refractory acute leukaemia with aclacinomycin A.

Rowe JM, Chang AY, Bennett JM. Rowe JM, et al. Bone Marrow Transplant. 1989 Dec;4 Suppl 3:47-8. Bone Marrow Transplant. 1989. PMID: 2627607 No abstract available.

6

Refractory acute lymphocytic leukemia: response to aclacinomycin A and VP-16-213.

Rowe JM, Chang AY, Bennett JM. Rowe JM, et al. Hematol Oncol. 1989 Nov-Dec;7(6):405-10. doi: 10.1002/hon.2900070603. Hematol Oncol. 1989. PMID: 2807178

7

Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia.

Rowe JM, Chang AY, Bennett JM. Rowe JM, et al. Blood. 1988 Apr;71(4):992-6. Blood. 1988. PMID: 3162695 Free article.

8

Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation.

Lazarus HM, Rowe JM. Lazarus HM, et al. Among authors: rowe jm. Blood Rev. 1994 Sep;8(3):169-78. doi: 10.1016/0268-960x(94)90078-v. Blood Rev. 1994. PMID: 7529606 Review.

9

New and experimental therapies for treating graft-versus-host disease.

Lazarus HM, Rowe JM. Lazarus HM, et al. Among authors: rowe jm. Blood Rev. 1995 Jun;9(2):117-33. doi: 10.1016/s0268-960x(95)90031-4. Blood Rev. 1995. PMID: 7580389 Free article. Review. No abstract available.

10

Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.

Tallman MS, Gray R, Bennett JM, Variakojis D, Robert N, Wood WC, Rowe JM, Wiernik PH. Tallman MS, et al. Among authors: rowe jm. J Clin Oncol. 1995 Jul;13(7):1557-63. doi: 10.1200/JCO.1995.13.7.1557. J Clin Oncol. 1995. PMID: 7602344 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

494 results

Search Page

Filters